Breaking News

Tufts Study Boasts Growth in Big Pharma Biotech Products

Driven by new technologies, improved outcomes, and small molecule patent losses

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The pharmaceutical industry, namely Big Pharma, has dramatically shifted its R&D focus from small molecule drugs to include a rapidly increasing number of biotechnology products, according to a new analysis from the Tufts Center for the Study of Drug Development. Tufts CSDD found that biotech products accounted for 7% of revenue generated by the top 10 selling pharmaceutical-biotech products worldwide in 2001, and accounted for 71% in 2012. The transformation, according to Tufts CSDD direct...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters